SB0030 Engrossed LRB095 04252 RLC 24293 b

1     AN ACT concerning criminal law.
 
2     Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
 
4     Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 316, 317, 318, 319, and 320 and by
6 adding Section 321 as follows:
 
7     (720 ILCS 570/316)
8     Sec. 316. Schedule II controlled substance prescription
9 monitoring program.
10     The Department must provide for a Schedule II controlled
11 substance prescription monitoring program that includes the
12 following components:
13         (1) The Each time a Schedule II controlled substance is
14     dispensed, the dispenser must transmit to the central
15     repository the following information:
16             (A) The recipient's name.
17             (B) The recipient's address.
18             (C) The national drug code number of the Schedule
19         II controlled substance dispensed.
20             (D) The date the Schedule II controlled substance
21         is dispensed.
22             (E) The quantity of the Schedule II controlled
23         substance dispensed.

 

 

SB0030 Engrossed - 2 - LRB095 04252 RLC 24293 b

1             (F) The dispenser's United States Drug Enforcement
2         Administration Agency registration number.
3             (G) The prescriber's United States Drug
4         Enforcement Administration Agency registration number.
5         (2) The information required to be transmitted under
6     this Section must be transmitted not more than 7 15 days
7     after the date on which a Schedule II controlled substance
8     is dispensed.
9         (3) A dispenser must transmit the information required
10     under this Section by:
11             (A) an electronic device compatible with the
12         receiving device of the central repository;
13             (B) a computer diskette;
14             (C) a magnetic tape; or
15             (D) a pharmacy universal claim form or Pharmacy
16         Inventory Control form;
17     that meets specifications prescribed by the Department.
18     Controlled Schedule II controlled substance prescription
19 monitoring does not apply to Schedule II controlled substance
20 prescriptions as exempted under Section 313.
21 (Source: P.A. 91-576, eff. 4-1-00; 91-714, eff. 6-2-00.)
 
22     (720 ILCS 570/317)
23     Sec. 317. Central repository for collection of
24 information.
25     (a) The Department must designate a central repository for

 

 

SB0030 Engrossed - 3 - LRB095 04252 RLC 24293 b

1 the collection of information transmitted under Section 316 and
2 321.
3     (b) The central repository must do the following:
4         (1) Create a database for information required to be
5     transmitted under Section 316 in the form required under
6     rules adopted by the Department, including search
7     capability for the following:
8             (A) A recipient's name.
9             (B) A recipient's address.
10             (C) The national drug code number of a controlled
11         substance dispensed.
12             (D) The dates a Schedule II controlled substance is
13         dispensed.
14             (E) The quantities of a Schedule II controlled
15         substance dispensed.
16             (F) A dispenser's United States Drug Enforcement
17         Administration Agency registration number.
18             (G) A prescriber's United States Drug Enforcement
19         Administration Agency registration number.
20         (2) Provide the Department with a continuing 24 hour a
21     day on-line access to the database maintained by the
22     central repository. The Department of Financial and
23     Professional Regulation must provide the Department with
24     electronic access to the license information of a
25     prescriber or dispenser. The Department of Financial and
26     Professional Regulation may charge a fee for this access

 

 

SB0030 Engrossed - 4 - LRB095 04252 RLC 24293 b

1     not to exceed the actual cost of furnishing the
2     information.
3         (3) Secure the information collected by the central
4     repository and the database maintained by the central
5     repository against access by unauthorized persons.
6     No fee shall be charged for access by a prescriber or
7 dispenser.
8 (Source: P.A. 91-576, eff. 4-1-00.)
 
9     (720 ILCS 570/318)
10     Sec. 318. Confidentiality of information.
11     (a) Information received by the central repository under
12 Section 316 and 321 is confidential.
13     (b) The Department must carry out a program to protect the
14 confidentiality of the information described in subsection
15 (a). The Department may disclose the information to another
16 person only under subsection (c), (d), or (f) and may charge a
17 fee not to exceed the actual cost of furnishing the
18 information.
19     (c) The Department may disclose confidential information
20 described in subsection (a) to any person who is engaged in
21 receiving, processing, or storing the information.
22     (d) The Department may release confidential information
23 described in subsection (a) to the following persons:
24         (1) A governing body that licenses practitioners and is
25     engaged in an investigation, an adjudication, or a

 

 

SB0030 Engrossed - 5 - LRB095 04252 RLC 24293 b

1     prosecution of a violation under any State or federal law
2     that involves a controlled substance.
3         (2) An investigator for the Consumer Protection
4     Division of the office of the Attorney General, a
5     prosecuting attorney, the Attorney General, a deputy
6     Attorney General, or an investigator from the office of the
7     Attorney General, who is engaged in any of the following
8     activities involving controlled substances:
9             (A) an investigation;
10             (B) an adjudication; or
11             (C) a prosecution of a violation under any State or
12         federal law that involves a controlled substance.
13         (3) A law enforcement officer who is:
14             (A) authorized by the Department of State Police to
15         receive information of the type requested for the
16         purpose of investigations involving controlled
17         substances;
18             (B) approved by the Department to receive
19         information of the type requested for the purpose of
20         investigations involving controlled substances; and
21             (C) engaged in the investigation or prosecution of
22         a violation under any State or federal law that
23         involves a controlled substance.
24     (e) Before the Department releases confidential
25 information under subsection (d), the applicant must
26 demonstrate in writing to the Department that:

 

 

SB0030 Engrossed - 6 - LRB095 04252 RLC 24293 b

1         (1) the applicant has reason to believe that a
2     violation under any State or federal law that involves a
3     Schedule II controlled substance has occurred; and
4         (2) the requested information is reasonably related to
5     the investigation, adjudication, or prosecution of the
6     violation described in subdivision (1).
7     (f) The Department may release to:
8         (1) a governing body that licenses practitioners;
9         (2) an investigator for the Consumer Protection
10     Division of the office of the Attorney General, a
11     prosecuting attorney, the Attorney General, a deputy
12     Attorney General, or an investigator from the office of the
13     Attorney General; or
14         (3) a law enforcement officer who is:
15             (A) authorized by the Department of State Police to
16         receive the type of information released; and
17             (B) approved by the Department to receive the type
18         of information released; or
19         (4) prescription monitoring entities in other states
20     per the provisions outlined in subsection (g) and (h)
21     below;
22 confidential prescription record information collected under
23 Sections 316 and 321 generated from computer records that
24 identifies vendors or practitioners, or both, who are
25 prescribing or dispensing large quantities of a Schedule II,
26 III, IV, or V controlled substances outside the scope of their

 

 

SB0030 Engrossed - 7 - LRB095 04252 RLC 24293 b

1 practice, pharmacy, or business, substance as determined by the
2 Advisory Committee created by Section 320.
3     (g) The information described in subsection (f) may not be
4 released until it has been reviewed by an employee of the
5 Department who is licensed as a prescriber or a dispenser and
6 until that employee has certified that further investigation is
7 warranted. However, failure to comply with this subsection (g)
8 does not invalidate the use of any evidence that is otherwise
9 admissible in a proceeding described in subsection (h).
10     (h) An investigator or a law enforcement officer receiving
11 confidential information under subsection (c), (d), or (f) may
12 disclose the information to a law enforcement officer or an
13 attorney for the office of the Attorney General for use as
14 evidence in the following:
15         (1) A proceeding under any State or federal law that
16     involves a Schedule II controlled substance.
17         (2) A criminal proceeding or a proceeding in juvenile
18     court that involves a Schedule II controlled substance.
19     (i) The Department may compile statistical reports from the
20 information described in subsection (a). The reports must not
21 include information that identifies, by name, license or
22 address, any practitioner, dispenser, ultimate user, or other
23 person administering a controlled substance.
24     (j) Based upon federal, initial and maintenance funding, a
25 prescriber and dispenser inquiry system shall be developed to
26 assist the medical community in its goal of effective clinical

 

 

SB0030 Engrossed - 8 - LRB095 04252 RLC 24293 b

1 practice and to prevent patients from diverting or abusing
2 medications.
3         (1) An inquirer shall have read-only access to a
4     stand-alone database which shall contain records for the
5     previous 6 months.
6         (2) Dispensers may, upon positive and secure
7     identification, make an inquiry on a patient or customer
8     solely for a medical purpose as delineated within the
9     federal HIPAA law.
10         (3) The Department shall provide a one-to-one secure
11     link and encrypted software necessary to establish the link
12     between an inquirer and the Department. Technical
13     assistance shall also be provided.
14         (4) Written inquiries are acceptable but must include
15     the fee and the requestor's Drug Enforcement
16     Administration license number and submitted upon the
17     requestor's business stationary.
18         (5) No data shall be stored in the database beyond 24
19     months.
20         (6) Tracking analysis shall be established and used per
21     administrative rule.
22         (7) Nothing in this Act or Illinois law shall be
23     construed to require a prescriber or dispenser to make use
24     of this inquiry system.
25         (8) If there is an adverse outcome because of a
26     prescriber making an inquiry, which is initiated in good

 

 

SB0030 Engrossed - 9 - LRB095 04252 RLC 24293 b

1     faith, the prescriber shall be held harmless from any civil
2     liability.
3 (Source: P.A. 91-576, eff. 4-1-00.)
 
4     (720 ILCS 570/319)
5     Sec. 319. Rules. The Department must adopt rules under the
6 Illinois Administrative Procedure Act to implement Sections
7 316 through 321 318, including the following:
8         (1) Information collection and retrieval procedures
9     for the central repository, including the Schedule II
10     controlled substances to be included in the program
11     required under Section 316 and 321.
12         (2) Design for the creation of the database required
13     under Section 317.
14         (3) Requirements for the development and installation
15     of on-line electronic access by the Department to
16     information collected by the central repository.
17 (Source: P.A. 91-576, eff. 4-1-00.)
 
18     (720 ILCS 570/320)
19     Sec. 320. Advisory committee.
20     (a) The Secretary of Human Services must appoint an
21 advisory committee to assist the Department in implementing the
22 Schedule II controlled substance prescription monitoring
23 program created by Section 316 and 321 of this Act. The
24 Advisory Committee consists of prescribers and dispensers.

 

 

SB0030 Engrossed - 10 - LRB095 04252 RLC 24293 b

1     (b) The Secretary of Human Services must determine the
2 number of members to serve on the advisory committee. The
3 Secretary must choose one of the members of the advisory
4 committee to serve as chair of the committee.
5     (c) The advisory committee may appoint its other officers
6 as it deems appropriate.
7     (d) The members of the advisory committee shall receive no
8 compensation for their services as members of the advisory
9 committee but may be reimbursed for their actual expenses
10 incurred in serving on the advisory committee.
11 (Source: P.A. 91-576, eff. 4-1-00.)
 
12     (720 ILCS 570/321 new)
13     Sec. 321. Schedule III, IV, and V controlled substance
14 prescription monitoring program.
15     (a) The Department shall provide for a Schedule III, IV,
16 and V controlled substances prescription monitoring program
17 contingent upon full funding from the authorized federal agency
18 less incidental expenses.
19     (b) Prescription data collected for Schedules III, IV, and
20 V shall include the components listed in Section 316(1), (2),
21 and (3).
22     (c) The information required to be transmitted under this
23 Section must be transmitted not more than 7 days after the date
24 on which a controlled substance is dispensed.
25     (d) If federal funding is not provided, the Department

 

 

SB0030 Engrossed - 11 - LRB095 04252 RLC 24293 b

1 shall cease data collection for Schedules III, IV, and V.
2     (e) All requirements for this Section shall comply with the
3 federal HIPAA statute.